• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    9/18/23 1:25:03 PM ET
    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Engineering & Construction
    Industrials
    Metal Fabrications
    Industrials
    Get the next $AENZ alert in real time by email

    Gainers

    SCWorx Corp. (NASDAQ:WORX) shares jumped 111% to $0.4000.

    Avinger, Inc. (NASDAQ:AVGR) surged 63.2% to $6.75 amid the company announcing the commercial launch of its Tigereye ST image-guided CTO crossing device.

    SeqLL Inc. (NASDAQ:SQL) shares climbed 47.2% to $19.50 after the company announced the date of its cash and stock dividend.

    Perspective Therapeutics, Inc. (NASDAQ:CATX) shares climbed 39.1% to $0.2851 after falling 42% on Friday.

    Nikola Corporation (NASDAQ:NKLA) rose 33% to $1.58 after the company announced the appointment of a new chief operating officer.

    MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) gained 29.1% to $3.90. Mira Pharmaceuticals shared data and research that positions MIRA1a as a potential future alternative prescription medication with properties not found in THC as well as the potential for fewer side effects.

    T2 Biosystems, Inc. (NASDAQ:TTOO) shares climbed 26.7% to $0.3513. T2 Biosystems said it issued inducement awards to four new employees.

    Trinity Place Holdings Inc. (NYSE:TPHS) gained 18.7% to $0.4690.

    ContraFect Corporation (NASDAQ:CFRX) jumped 18.3% to $0.67. ContraFect reported submission of IND application to the FDA for its development candidate CF-370.

    Kineta, Inc. (NASDAQ:KA) gained 16.1% to $2.24. Kineta announced a new research agreement to evaluate VISTA Biomarker Expression.

    Green Plains Partners LP (NASDAQ:GPP) jumped 16% to $15.98 after entering a definitive merger agreement with
    Green Plains Inc. (NASDAQ:GPRE).

    Cabaletta Bio, Inc. (NASDAQ:CABA) surged 13.4% to $17.92. Wells Fargo maintained Cabaletta Bio with an Overweight and raised the price target from $14 to $39.

    Amprius Technologies, Inc. (NYSE:AMPX) rose 13.2% to $4.4699.

    Aenza S.A.A. (NYSE:AENZ) gained 13.1% to $2.59.

    China Green Agriculture, Inc. (NYSE:CGA) surged 13.1% to $1.99.

    Vivani Medical, Inc. (NASDAQ:VANI) gained 11.9% to $0.9850.

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) jumped 11.6% to $5.88. Iovance Biotherapeutics Director Wayne P Rothbaum acquired a total of 5,000,000 shares an average price of $5.30.

    Matinas BioPharma Holdings, Inc. (NYSE:MTNB) rose 11.5% to $0.1450.

    Cibus, Inc. (NASDAQ:CBUS) gained 11.4% to $18.62.

    MariaDB plc (NYSE:MRDB) surged 9.4% to $0.4678. The board of MariaDB confirms that it has received an unsolicited non-binding indicative proposal from Runa Capital II to acquire 100% of the issued 67,705,445 ordinary shares of the company other than those shares already owned by Runa.

    TradeUP Acquisition Corp. (NASDAQ:UPTD) shares climbed 9.1% to $9.51 after falling 29% on Friday.

    Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) gained 8.3% to $1.17.

    ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) surged 8.1% to $11.90. JP Morgan upgraded ZIM Integrated Shipping from Neutral to Overweight and announced a $15.4 price target.

    Losers

    Earlyworks Co., Ltd (NASDAQ:ELWS) shares dipped 36.2% to $0.8427. Earlyworks, during July, priced its IPO of 1.2 million ADSs at $5.00 per ADS.

    STRATA Skin Sciences, Inc. (NASDAQ:SSKN) fell 30.9% to $0.6911.

    AERWINS Technologies Inc. (NASDAQ:AWIN) shares fell 25.4% to $0.1439 after surging 50% on Friday.

    MSP Recovery, Inc. (NASDAQ:LIFW) shares fell 21.7% to $0.1472 after jumping around 238% on Friday.

    AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) fell 21.4% to $0.1139. AgriFORCE Growing Systems announced commercial launch and first purchase order for its AgriFORCE-RCS Hydroxyl Device.

    Scilex Holding Company (NASDAQ:SCLX) declined 17.3% to $1.86. Scilex recently announced the completion of its SP-103 Phase 2 study to evaluate the safety and efficacy in subjects with acute LBP.

    Rubicon Technologies, Inc. (NYSE:RBT) fell 17.2% to $0.3580. Rubicon Technologies reported a 1-for-8 reverse stock split.

    Chanson International Holding (NASDAQ:CHSN) declined 16.3% to $2.76.

    Ayro, Inc. (NASDAQ:AYRO) fell 15% to $3.30.

    Canopy Growth Corporation (NASDAQ:CGC) tumbled 14.8% to $1.15 after the company announced a private placement of up to $50 million.

    UpHealth, Inc. (NYSE:UPH) fell 14.5% to $1.0256.

    Micromobility.com Inc. (NASDAQ:MCOM) dipped 14.1% to $0.0704.

    Tenax Therapeutics, Inc. (NASDAQ:TENX) tumbled 14.1% to $0.2922.

    NexImmune, Inc. (NASDAQ:NEXI) declined 13.8% to $0.2241.

    Sezzle Inc. (NASDAQ:SEZL) fell 13.5% to $11.61.

    Cara Therapeutics, Inc. (NASDAQ:CARA) dipped 13.4% to $2.0250.

    Nuvalent, Inc. (NASDAQ:NUVL) fell 12.7% to $41.36. Nuvalent will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 trial of Nvl-655 at the 35th AACR-NCI-EORTC Symposium.

    FOXO Technologies Inc. (NASDAQ:FOXO) fell 11% to $0.1219 after gaining 11% on Friday.

    DocGo Inc. (NASDAQ:DCGO) fell 10.4% to $5.11. DocGo named Lee Bienstock as CEO effective Sept. 15.

    GigaCloud Technology Inc. (NASDAQ:GCT) fell 10.2% to $10.28.

    Eos Energy Enterprises, Inc. (NASDAQ:EOSE) declined 9.8% to $2.3350.

    Unity Software Inc. (NYSE:U) fell 8.8% to $33.13. On Sept. 17,Unity posted “.. We apologize for the confusion and angst the runtime fee policy we announced on Tuesday caused. We are listening, talking to our team members, community, customers, and partners, and will be making changes to the policy.”

    Safety Shot Inc (NASDAQ:SHOT) fell 8.5% to $1.40.

    180 Life Sciences Corp. (NASDAQ:ATNF) fell 6.8% to $0.7713 after climbing 45% on Friday.

    Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shares fell 6.4% to $0.36 after surging 25% on Friday.

    OKYO Pharma Limited (NASDAQ:OKYO) fell 5.1% to $1.88. OKYO Pharma announced closing of $4.0 million registered direct offering of ordinary shares.

    Now Read This: Wall Street's Most Accurate Analysts Say Buy These 3 Tech Stocks With Over 3% Dividend Yields

    Get the next $AENZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AENZ
    $AGRI
    $AMPX
    $ATNF

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    Unity Software Inc.
    $U
    3/3/2026$19.00Underperform → Neutral
    BofA Securities
    Eos Energy Enterprises Inc.
    $EOSE
    2/27/2026$20.00Buy → Neutral
    Guggenheim
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Amprius Technologies Inc.
    $AMPX
    2/23/2026$17.00Buy
    Craig Hallum
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    More analyst ratings

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Balcom Alexandra

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    3/26/26 4:30:12 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sun Kang

    4 - Amprius Technologies, Inc. (0001899287) (Issuer)

    3/24/26 7:11:33 PM ET
    $AMPX
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 4 filed by Sabzivand Amin

    4 - Sezzle Inc. (0001662991) (Issuer)

    3/24/26 4:39:50 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139. ALAMEDA, Calif., March 26

    3/26/26 4:16:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Unity Releases Preliminary First Quarter Results Exceeding Guidance; Will Enhance Growth and Profitability by Exiting Non-Strategic Ad Businesses

    Unity (NYSE:U), the world's leading game engine, today announced preliminary revenue and Adjusted EBITDA for the first quarter 2026 above guidance. Unity expects to report revenue of $505 Million to $508 Million, compared to guidance of $480 Million to $490 Million. Unity expects Adjusted EBITDA of $130 Million to $135 Million, compared to guidance of $105 Million to $110 Million, representing year-over-year growth of 58%. The outperformance is driven by Unity Vector, which is expected to increase 15% sequentially in the first quarter of 2026, as well as better than expected performance in Create. Unity expects Grow revenue of approximately $352 Million and Create revenue of approximately

    3/26/26 4:05:00 PM ET
    $U
    Computer Software: Prepackaged Software
    Technology

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unity Software upgraded by BofA Securities with a new price target

    BofA Securities upgraded Unity Software from Underperform to Neutral and set a new price target of $19.00

    3/3/26 8:20:38 AM ET
    $U
    Computer Software: Prepackaged Software
    Technology

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,683,335 worth of shares (1,575,231 units at $1.07) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    3/16/26 6:15:46 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Director Sweeney Patrick Francis bought $101,298 worth of shares (6,383 units at $15.87), increasing direct ownership by 18% to 42,719 units (SEC Form 4)

    4 - Green Plains Inc. (0001309402) (Issuer)

    3/9/26 9:19:55 AM ET
    $GPRE
    Major Chemicals
    Industrials

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    SEC Filings

    View All

    SEC Form DEFA14A filed by Unity Software Inc.

    DEFA14A - Unity Software Inc. (0001810806) (Filer)

    3/27/26 4:21:57 PM ET
    $U
    Computer Software: Prepackaged Software
    Technology

    SEC Form DEF 14A filed by Unity Software Inc.

    DEF 14A - Unity Software Inc. (0001810806) (Filer)

    3/27/26 4:19:23 PM ET
    $U
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Unity Software Inc.

    SCHEDULE 13G/A - Unity Software Inc. (0001810806) (Subject)

    3/27/26 1:52:18 PM ET
    $U
    Computer Software: Prepackaged Software
    Technology

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Eos Energy Enterprises Appoints Nathaniel Fick to Board of Directors

    PITTSBURGH, March 26, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS), today announced the appointment of Nathaniel (Nate) Fick to its Board of Directors as an independent Common Class III director, effective March 24, 2026. Fick brings extensive leadership experience spanning national security, technology, cybersecurity, artificial intelligence (AI), and complex infrastructure—capabilities increasingly relevant as energy storage becomes embedded in critical grid operations. Fick currently

    3/26/26 8:45:00 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend

    HAIFA, Israel, March 19, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place on March 26, 2026, as previously announced by the Company on March 9, 2026 (the "Dividend"), the previously obtained tax ruling from the Israeli Tax Authority ("ITA") on tax withholding procedures relating to the payment of the Dividend to the Company's shareholders (the "Ruling"), as extended, shall apply.   As a result of the Ruling, certain shareholders of the Company ("Shareholders") may be eligible to a reduced Israeli withholding tax rate

    3/19/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Financials

    Live finance-specific insights

    View All

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat

    3/19/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AENZ
    $AGRI
    $AMPX
    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary